よくわかる血栓・止血異常の診療

出版社： 中山書店
著者：
発行日： 2014-11-20
分野： 臨床医学：内科  >  血液
ISBN： 9784521737805
電子書籍版： 2014-11-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

12,100 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

12,100 円(税込)

購入する

商品紹介

血友病，特発性血小板減少性紫斑病，静脈血栓塞栓症，抗リン脂質抗体症候群，DICなどの主な出血性疾患と血栓性疾患を，血栓止血学のエキスパートが診断から治療までわかりやすく解説する．また，図表を多用して止血機構の基礎知識や凝固系検査値の読み方を詳述するほか，新規経口抗凝固薬，トロンボモジュリン製剤，血液製剤などの進展する薬剤についても解説する．

目次

  • よくわかる血栓・止血異常の診療

    ―目次―

    第1章　血栓・止血異常症を理解するために
    　血栓・止血機構オーバービュー
    　凝固反応を理解する
    　血小板による止血・血栓形成を理解する
    　線溶反応とは

    第2章　出血性疾患
    　凝固因子の異常
    　　血友病
    　　後天性血友病A
    　　von Willebrand病
    　　まれな凝固因子異常症
    　血小板の異常
    　　特発性血小板減少性紫斑病（ITP)
    　　血小板機能異常症
    　　先天性血小板減少症

    第3章　血栓性疾患
    　静脈血栓塞栓症の診断と予防，治療
    　凝固阻止因子欠乏症/異常症
    　線溶系異常症
    　本態性血小板血症/多血症

    第4章　血小板減少を伴う血栓性疾患
    　血栓性血小板減少性紫斑病（TTP)
    　抗リン脂質抗体症候群
    　播種性血液凝固症候群（DIC）
    　　血液疾患とDIC
    　ヘパリン起因性血小板減少症

    第5章　標準治療と新規薬剤
    　抗血小板薬
    　抗凝固薬
    　トロンボモジュリン製剤の使用の位置づけ
    　血小板輸血の実際
    　新鮮凍結血漿使用の実際

    第6章　血栓・止血の検査値をどう読むか
    　出血性疾患における検査値異常とその意義
    　血栓性疾患における検査値異常とその意義
    　皮膚症状からみた血栓止血異常症

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 血栓・止血異常症を理解するために

P.13 掲載の参考文献
1) Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008 ; 359 : 938-49.
PubMed
2) Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest 2012 ; 122 : 2331-6.
PubMed
3) Schulz C, et al. Crossroads of coagulation and innate immunity : the case of deep vein thrombosis. J Thromb Haemost 2013 ; 11 Suppl 1 : 233-41.
 
4) Esmon CT, Esmon NL. The link between vascular features and thrombosis. Annu Rev Physiol 2011 ; 73 : 503-14.
PubMed
5) Bovill EG, van der Vliet A. Venous valvular stasis-associated hypoxia and thrombosis : what is the link? Annu Rev Physiol 2011 ; 73 : 527-45.
PubMed
P.22 掲載の参考文献
1) Wang GR, et al. Mechanism of platelet inhibition by nitric oxide : in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci USA 1998 ; 95 : 4888-93.
PubMed
2) Poole A, et al. The Fc receptor γ-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 1997 ; 16 : 2333-41.
 
3) Wu Y, et al. Role of Fc receptor γ-chain in platelet glycoprotein Ib-mediated signaling. Blood 2001 ; 97 : 3836-45.
 
4) Ikeda Y, et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991 ; 87 : 1234-40.
PubMed
5) Clemetson JM, et al. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcαR and the natural killer receptors. J Biol Chem 1999 ; 274 : 29019-24.
 
6) Chen D, et al. Molecular mechanism of platelet exocytosis : role of SNAP-23 and syntaxin 2 in dense core granule release. Blood 2000 ; 95 : 921-9.
PubMed
7) Watanabe N, et al. Mechanisms and consequences of agonist-induced talin recruitment to platelet integrin αIIbβ3. J Cell Biol 2008 ; 181 : 1211-22.
 
P.34 掲載の参考文献
American College of Emergency Physicians ; American Academy of Neurology. Clinical Policy : Use of intravenous tPA for the management of acute ischemic stroke in the emergency department. Ann Emerg Med 2013 ; 61 : 225-43.
PubMed
Alberts MJ. Cerebral hemorrhage, warfarin, and intravenous tPA : the real risk is not treating. JAMA 2012 ; 307 : 2637-9.
 
Ford AL, et al. Reducing door-to-needle times using Toyota's lean manufacturing principles and value stream analysis. Stroke 2012 ; 43 : 3395-8.
 
Kawata H, et al. A new drug delivery system for intravenous coronary thrombolysis with thrombus targeting and stealth activity recoverable by ultrasound. J Am Coll Cardiol 2012 ; 60 : 2550-7.
 
Lippi G, et al. Novel and emerging therapies : thrombus-targeted fibrinolysis. Semin Thromb Hemost 2013 ; 39 : 48-58.
PubMed
Millard WB. New guidelines on tPA in stroke : putting out fires with gasoline? Ann Emerg Med 2013 ; 62 : A13-8.
PubMed
Ramaiah SS, Yan B. Low-dose tissue plasminogen activator and standard-dose tissue plasminogen activator in acute ischemic stroke in Asian populations : a review. Cerebrovasc Dis 2013 ; 36 : 161-6.
PubMed
Saver JL, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 2013 ; 309 : 2480-8.
PubMed
Yeo LL, et al. Timing of recanalization after intravenous thrombolysis and functional outcomes after acute ischemic stroke. JAMA Neurol 2013 ; 70 : 353-8.
PubMed
Suzuki Y, et al. Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells. Blood 2009 ; 113 : 470-8.
PubMed

第2章 出血性疾患

P.44 掲載の参考文献
1) 藤井輝久ほか. インヒビターのない血友病患者に対する止血治療ガイドライン : 2013年改訂版. 血栓止血誌2013 ; 24 : 619-39.
 
2) Gouw SC, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013 ; 368 ; 231-9.
PubMed
3) Manco-Johnson MJ, et al. Prophylaxis versus episodic treatment to prevent joint dis ease in boys with severe hemophilia. N Engl J Med 2007 ; 357 : 535-44.
 
4) 酒井道生ほか. インヒビター保有先天性血友病患者に対する止血治療ガイドライン : 2013年改訂版. 血栓止血誌2013 ; 24 : 640-58.
 
5) 嶋緑倫. 血友病診療の展望-個別化治療の必要性. 臨床血液 2012 ; 53 : 1737-44.
 
6) Hilden I, et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 2012 ; 119 : 5871-8.
 
7) Kitazawa T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012 ; 18 : 1570-4.
 
8) Hay CR, et al. The principal results of the International Immune Tolerance Study : a randomized dose comparison. Blood 2012 ; 119 : 1335-44.
PubMed
9) Ettingshausen CE, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis 2005 ; 16 Suppl 1 : S27-31.
 
10) Gringeri A, et al. Immune tolerance induction with a high purity von Willebrand factor/factor VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007 ; 13 : 373-9.
PubMed
11) DiMichele DM, et al. The North American Immune Tolerance Registry : practices, outcomes, outcome predictors. Thromb Haemost 2002 ; 87 : 52-7.
PubMed
P.56 掲載の参考文献
1) Collins PW, et al. Acquired hemophilia A in the United Kingdom : a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007 ; 109 : 1870-7.
PubMed
2) 嶋緑倫ほか. 本邦における血液凝固後天性インヒビターの実態. 血栓止血誌 2003 ; 14 : 107-21.
 
3) 田中一郎ほか. わが国における後天性凝固因子インヒビターの実態に関する3年間の継続調査-予後因子に関する検討. 血栓止血誌 2008 ; 19 : 140-53.
 
4) Knoebl P, et al. Demographic and clinical data in acquired hemophilia A : results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012 ; 10 : 622-31.
PubMed
5) 田中一郎ほか. 後天性血友病 A 診療ガイドライン. 血栓止血誌 2011 ; 22 : 295-322.
 
6) Collins P, et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes 2010 ; 3 : 161-8.
PubMed
7) Huth-Kuhne A, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009 ; 94 : 566-75.
PubMed
P.65 掲載の参考文献
1) Jaffe EA, et al. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci U S A 1974 ; 71 : 1906-9.
PubMed
2) Nachman R, et al. Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. J Clin Invest 1977 ; 60 : 914-21.
PubMed
3) Marchese P, et al. Identification of three tyrosine residues of glycoprotein Ibα with distinct roles in von Willebrand factor and α-thrombin binding. J Biol Chem 1995 ; 270 : 9571-8.
 
4) Scott JP, et al. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. J Biol Chem 1991 ; 266 : 8149-55.
PubMed
5) Berndt MC, et al. Ristocetin-dependent reconstitution of binding of von Willebrand factor to purified human platelet membrane glycoprotein Ib-IX complex. Biochemistry 1988 ; 27 : 633-40.
 
6) Fujimura Y, et al. von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem 1986 ; 261 : 381-5.
 
7) Matsushita T, Sadler JE. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor. J Biol Chem 1995 ; 270 : 13406-14.
PubMed
8) Kroner PA, Frey AB. Analysis of the structure and function of the von Willebrand factor A1 domain using targeted deletions and alanine-scanning mutagenesis. Biochemstry 1996 ; 35 : 13460-8.
 
9) Matsushita T, et al. Localization of von Willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis. J Biol Chem 2000 ; 275 : 11044-9.
PubMed
10) Lollar P, et al. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988 ; 263 : 10451-5.
PubMed
11) Leyte A, et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 1991 ; 266 : 740-6.
PubMed
12) Yee A, et al. A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice. Blood 2014 ; 124 : 445-52.
 
13) Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994 ; 71 : 520-5.
PubMed
14) Johnsen JM, et al. Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans : the NHLBI Exome Sequencing Project. Blood 2013 ; 122 : 590-7.
PubMed
15) Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998 ; 67 : 395-424.
PubMed
16) Gill JC, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987 ; 69 : 1691-5.
PubMed
17) Legendre P, et al. Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein. Blood 2013 ; 121 : 2135-43.
PubMed
18) O'Brien LA, et al. Theoretical structural explanation for Group I and Group II, type 2A von Willebrand disease mutations. J Thromb Haemost 2005 ; 3 : 796-7.
 
19) Kashiwagi T, et al. L1503R is a member of group I mutation and has dominantnegative effect on secretion of full-length VWF multimers : an analysis of two patients with type 2A von Willebrand disease. Haemophilia 2008 ; 14 : 556-63.
 
20) Ruggeri ZM, et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980 ; 302 : 1047-51.
 
21) Rabinowitz I, et al. Type IIB mutation His-505 → Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem 1993 ; 268 : 20497-501.
 
22) Nishino M, et al. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989 ; 74 : 1591-9.
PubMed
23) M azurier C, et al. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood 1990 ; 75 : 20-6.
 
24) Mannucci PM, et al. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Haematol 1987 ; 39 : 467-70.
 
25) Mohri H, et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998 ; 91 : 3623-9.
 
26) Casonato A, et al. von Willebrand factor abnormalities in aortic valve stenosis : pathophysiology and impact on bleeding. Thrombosis and haemostasis 2011 ; 106 : 58-66.
PubMed
27) Budde U, et al. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993 ; 82 : 1749-57.
PubMed
28) Budde U, et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984 ; 64 : 981-5.
PubMed
29) van Genderen PJ, et al. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol 1996 ; 93 : 962-5.
 
30) van Genderen PJ, et al. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia : normalization after cytoreduction of the increased platelet count. Br J Haematol 1997 ; 99 : 832-6.
PubMed
31) van Genderen PJ, Leenknegt H. Normal binding of plasma von Willebrand factor to platelets in essential thrombocythemia. Am J Hematol 1999 ; 61 : 153-4.
PubMed
32) Lopez-Fernandez MF, et al. Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis. Thromb Haemost 1987 ; 58 : 753-7.
PubMed
P.79 掲載の参考文献
1) 瀧正志ほか. 血液凝固異常症全国調査 平成25年度報告書. 東京 : 財団法人エイズ予防財団 ; 2014.
 
2) Mannucci PM, et al. Recessively inherited coagulation disorders. Blood 2004 ; 104 : 1243-52.
PubMed
3) Peyvandi F, et al. Rare bleeding disorders. Haemophilia 2012 ; 18 : 148-53.
PubMed
4) Bolton-Maggs PH, et al. The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organization. Haemophilia 2004 ; 10 : 593-628.
PubMed
5) Miyawaki Y, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 2012 ; 366 : 2390-6.
PubMed
6) Endler G, et al. Evidence of a U-shaped association between factor XII activity and overall survival. J Thromb Haemost 2007 ; 5 : 1143-8.
 
7) Hayashi T, et al. A case of acquired FXIII deficiency with severe bleeding symptoms. Haemophilia 2012 ; 18 : 618-20.
PubMed
P.91 掲載の参考文献
1) 冨山佳昭ほか. 免疫性血小板減少性紫斑病の免疫病態. 臨床免疫・アレルギー科 2013 ; 59 : 649-57.
 
2) McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol 2007 ; 44 (Suppl 5) : S3-11.
 
3) Kurata Y, et al. Epidemiology of primary immune thrombocytopenia in children and adults in Japan : a population-based study and literature review. Int J Hematol 2011 ; 93 : 329-35.
PubMed
4) 冨山佳昭. トロンボポエチン受容体作動薬による難治性ITPの治療. 臨床血液2011 ; 52 : 627-32.
 
5) 藤村欣吾ほか. 成人特発性血小板減少性紫斑病治療の参照ガイド 2012年版. 臨床血液 2012 ; 53 : 433-42.
 
6) Vianelli N, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura : long-term results of 402 cases. Haematologica 2005 ; 90 : 72-7.
PubMed
7) Nurden AT, et al. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet 2009 ; 373 : 1562-9.
PubMed
P.104 掲載の参考文献
1) Shattil SJ, et al. The final steps of integrin activation : the end game. Nat Rev Mol Cell Biol 2010 ; 11 : 288-300.
PubMed
2) 柏木浩和, 冨山佳昭. 血栓形成の分子機構-血小板機能異常症の解析からみた最近の進歩. Pharma Medica 2012 ; 30 : 9-14.
Medical*Online
3) Nurden A, et al. Advances in our understanding of the molecular basis of disorders of platelet function. J Thromb Haemost 2011 ; 9 Suppl 1 : 76-91.
 
4) Nurden AT, et al. Glanzmann thrombasthenia : a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 2011 ; 118 : 5996-6005.
PubMed
5) Lanza F. Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy). Orphanet J Rare Dis 2006 ; 1 : 46.
PubMed
6) Moroi M, Jung SM. Platelet glycoprotein VI : its structure and function. Thromb Res 2004 ; 114 : 221-33.
PubMed
7) Takayama H, et al. A novel antiplatelet antibody therapy that induces cAMP-depedent endocytosis of the GPVI/Fc receptor γ-chain complex. J Clin Invest 2008 ; 118 : 1785-95.
 
8) Gunay-Aygun M, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules. Nat Genet 2011 ; 43 : 732-4.
 
9) Suzuki J, et al. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 2010 ; 468 : 834-8.
PubMed
10) Konkle BA. Acquired disorders of platelet function. Hematology Am Soc Hematol Educ Program 2011 ; 2011 : 391-6.
PubMed
P.112 掲載の参考文献
1) Balduini CL, et al. Diagnosis and management of inherited thrombocytopenias. Semin Thromb Hemost 2013 ; 39 : 161-71.
PubMed
2) Kunishima S, Saito H. Congenital macrothrombocytopenias. Blood Rev 2006 ; 20 : 111-21.
PubMed
3) Pecci A. Pathogenesis and management of inherited thrombocytopenias : rationale for the use of thrombopoietin-receptor agonists. Int J Hematol 2013 ; 98 : 34-47.
PubMed
4) Kunishima S, Saito H. Advances in the understanding of MYH9 disorders. Curr Opin Hematol 2010 ; 17 : 405-10.
PubMed
5) Kunishima S, et al. Genetic abnormalities of Bernard-Soulier syndrome. Int J Hematol 2002 : 76 : 319-27.
PubMed

第3章 血栓性疾患

P.121 掲載の参考文献
1) Sakon M, et al. Incidence of venous thromboembolism following major abdominal surgery : a multi-center, prospective epidemiological study in Japan. J Thromb Haemost. 2006 ; 4 : 581-6.
PubMed
2) Wells PS, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003 ; 349 : 1227-35.
PubMed
3) Le Gal G, et al. Prediction of pulmonary embolism in the emergency department : the revised Geneva score. Ann Intern Med 2006 ; 144 : 165-71.
PubMed
4) MacLean S, et al. Patient values and preferences in decision making for antithrombotic therapy : a systematic review : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 ; 141 : e1S-23S.
 
5) NICE. Venous thromboembolic diseases : the management of venous thromboembolic diseases and the role of thrombophilia testing. Clinical guidelines 144. London : National Institute for Health and Clinical Excellence. 2012. (http://www.nice.org.uk)
 
6) 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 【ダイジェスト版】肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2009年改訂版). 日本循環器学会 (http://www.j-circ.or.jp/guideline/index.html)
 
7) Khorana AA, et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005 ; 104 : 2822-9.
 
P.130 掲載の参考文献
1) 小嶋哲人. 血栓性疾患 先天性凝固阻止因子欠乏症 (antithrombin, protein C, protein S欠損症). 血栓止血誌 2009 ; 20 : 484-6.
 
2) Miyawaki Y, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 2012 ; 366 : 2390-6.
PubMed
3) Djordjevic V, et al. A novel prothrombin mutation in two families with prominent thrombophilia-the first cases of antithrombin resistance in a Caucasian population. J Thromb Haemost 2013 ; 11 : 1936-9.
 
4) Sakata T, et al. Protein C and antithrombin deficiency are important risk factors for deep vein thrombosis in Japanese. J Thromb Haemost 2004 ; 2 : 528-30.
PubMed
5) Sakata T, et al. Prevalence of protein S deficiency in the Japanese general population : the Suita Study. J Thromb Haemost 2004 ; 2 : 1012-3
 
6) 宮田敏行ほか. 日本人の血栓性素因, 特にプロテインS欠損症を中心に. 日産婦・新生児血会誌 2011 ; 20 : 75-82.
Medical*Online
7) Oosta GM, et al. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci USA 1981 ; 78 : 829-33.
PubMed
8) Comp PC, et al. Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986 ; 68 : 881-5.
PubMed
9) 鈴木敦夫, 小嶋哲人. エストロゲンによるProtein S産生抑制. 血栓止血誌 2011 ; 22 : 285-8.
 
10) 小林隆夫. 肺血栓塞栓症・深部静脈血栓症. 日産婦誌 2004 ; 56 : 382-91.
 
P.137 掲載の参考文献
1) 浦野哲盟. 線溶機序. 脈管学 2011 ; 51 : 293-9.
 
2) Mehta R, Shapiro AD. Plasminogen deficiency. Haemophilia 2008 ; 14 : 1261-8.
PubMed
3) Okamoto A, et al. Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese : the Suita Study. J Thromb Haemost 2003 ; 1 : 2397-403.
PubMed
4) Yamada Y, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002 ; 347 : 1916-23.
 
5) Aoki N. Discovery of α2-plasmin inhibitor and its congenital deficiency. J Thromb Haemost 2005 ; 3 : 623-31.
 
6) Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia 2008 ; 14 : 1190-200.
PubMed
7) Iwaki T, et al. Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost 2011 ; 9 : 1200-6.
PubMed
8) 一瀬白帝. 凝固13因子関連疾患の基礎と臨床-とくに後天性血友病 13 (出血性後天性凝固13因子欠乏症) について. 日本小児血液学会雑誌 2010 ; 24 : 3-13.
Medical*Online
P.148 掲載の参考文献
1) Thiele J, et al. Polycythaemia vera/Primary myelofibrosis/Essential thrombocythaemia. In : Swerdlow SH, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARC press ; 2008. pp.40-50.
 
2) Dan K, et al. Clinical features of polycythemia vera and essential thrombocythemia in Japan : retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. Int J Hematol 2006 ; 83 : 443-9.
 
3) Tefferi A, Spivak JL. Polycythemia vera : scientific advances and current practice. Semin Hematol 2005 ; 42 : 206-20.
PubMed
4) 薄井紀子ほか. 慢性骨髄性白血病/骨髄増殖性腫瘍 (CML/MPN). 日本血液学会, 編. 造血器腫瘍診療ガイドライン 2013年版. 東京 : 金原出版 ; 2013. pp.77-104.
 
5) Wolanskyj AP, et al. Essential thrombocythemia beyond the first decade : life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006 ; 81 : 159-66.
PubMed
6) McMahon B, Stein BL. Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Semin Thromb Hemost 2013 ; 39 : 101-11.
PubMed
7) 小松則夫. 骨髄増殖性腫瘍. 臨床血液 2013 ; 54 : 71-8.
 
8) 田丸智巳, 西川政勝. 本態性血小板血症 : 治療. 池田康夫, 編. 最新医学別冊 新しい診断と治療のABC63. 血小板減少症・増多症. 大阪 : 最新医学社 ; 2009. pp.65-73.
 

第4章 血小板減少を伴う血栓性疾患

P.163 掲載の参考文献
1) Furlan M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998 ; 339 : 1578-84.
PubMed
2) Matsumoto M, et al. Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS One 2012 ; 7 : e33029.
 
3) Matsumoto M, et al. Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress. Pathophysiol Haemost Thromb 2005 ; 34 : 35-40.
PubMed
4) Levy GG, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001 ; 413 : 488-94.
 
5) Kokame K, et al. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2004 ; 103 : 607-12.
PubMed
6) Yagi H, et al. Paradigm shift of childhood thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency. Presse Med 2012 ; 41 : e137-55.
PubMed
7) Rock GA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991 ; 325 : 393-7.
 
8) Matsumoto M, et al. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol 2004 ; 41 : 68-74.
PubMed
9) Scully M, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011 ; 118 : 1746-53.
 
Scully M, et al. Guideline on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012 ; 158 : 323-35.
PubMed
P.173 掲載の参考文献
1) Fujieda Y, et al. Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus 2012 ; 21 : 1506-14.
PubMed
2) Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 ; 4 : 295-306.
 
3) Matsuura E, et al. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994 ; 179 : 457-62.
 
4) de Groot PG, Urbanus RT. The significance of autoantibodies against β2-glycoprotein I. Blood 2012 ; 120 : 266-74.
 
5) Pengo V, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009 ; 7 : 1737-40.
PubMed
6) Atsumi T, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000 ; 43 : 1982-93.
PubMed
7) Otomo K, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012 ; 64 : 504-12.
PubMed
8) 中川育磨ほか. 抗リン脂質抗体症候群. Mebio 2013 ; 30 : 26-32.
Medical*Online
9) 古川真ほか. 抗リン脂質関連血小板減少症. 日本臨床免疫学会会誌 2003 ; 26 : 267-73.
 
10) Cervera R, et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II) : thrombocytopenia and skin manifestations. Lupus 2011 ; 20 : 174-81.
PubMed
11) Neunert C, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011 ; 117 : 4190-207.
PubMed
P.182 掲載の参考文献
1) Wada H. Disseminated intravascular coagulation. Clin Chim Acta 2004 ; 344 : 13-21.
PubMed
2) Taylor FB Jr, et al ; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001 ; 86 : 1327-30.
 
3) 和田英夫. 播種性血管内凝固症候群 (DIC). 浅野茂隆ほか, 監. 三輪血液病学. 東京 : 文光堂 ; 2006. pp.1743-52.
 
4) Brinkmann V, et al. Neutrophil extracellular traps kill bacteria. Science 2004 ; 303 : 1532-5.
PubMed
5) Takemitsu T, et al. Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb Haemost 2011 ; 105 : 40-4.
PubMed
6) Wada H, et al ; Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010 ; 125 : 6-11.
PubMed
7) Wada H, et al ; The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013 [Epub ahead of print].
 
P.192 掲載の参考文献
1) 朝倉英策. 播種性血管内凝固症候群 (DIC). 朝倉英策, 編. 臨床に直結する血栓止血学. 東京 : 中外医学社 ; 2013. pp.168-78.
 
2) 金沢大学血液内科・呼吸器内科. 血液・呼吸器内科のお役立ち情報. 播種性血管内凝固症候群 (DIC) <図解シリーズ>. http://www.3nai.jp/weblog/entry/24539.html
 
3) Kakkar AK, et al. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995 ; 346 : 1004-5.
PubMed
4) Menell JS, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999 ; 340 : 994-1004.
PubMed
5) Ikezoe T, et al. Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation. Leuk Res 2012 ; 36 : 1398-402.
PubMed
6) Ikezoe T, et al. Thrombomodulin enhances the antifibrinolytic and antileukemic effects of all-trans retinoic acid in acute promyelocytic leukemia cells. Exp Hematol 2012 ; 40 : 457-65.
PubMed
P.204 掲載の参考文献
1) Warkentin TE, Linkins LA. Non-necrotizing heparin-induced skin lesions and the 4T's score. J Thromb Haemost 2010 ; 8 : 1483-5.
 
2) Matsuo T, et al. Anti-heparin/PF4 complexes by ELISA in patients with disseminated intravascular coagulation. Pathophysiol Haemost Thromb 2007 ; 36 : 305-10.
PubMed
3) Cuker A, et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia : a systematic review and meta-analysis. Blood 2012 ; 120 : 4160-7.
PubMed
4) Minet V, et al. Assessment of the performances of AcuStar HIT and the combination with heparin-induced multiple electrode aggregometry : a retrospective study. Thromb Res 2013 ; 132 : 352-9.
PubMed
5) Althaus K, et al. Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia. Thromb Res 2013 ; 131 : e85-90.
PubMed
6) Legnani C, et al. Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia. Thromb Haemost 2010 ; 104 : 402-9.
PubMed
7) Davidson SJ, et al. Performance of a new, rapid, automated immunoassay for the detection of anti-platelet factor 4/heparin complex antibodies. Blood Coagul Fibrinolysis 2011 ; 22 : 340-4.
PubMed
8) Miyashita K, et al. Evaluation of three new fully automated quantitative immunoassays on diagnosis of heparin-induced thrombocytopenia. X Congress of ISTH. PB2.40-4. 2013. p.203.
 
9) 松尾武文. ヘパリン起因性血小板減少症における血小板第4因子 (PF4) /ポリアニオンを用いた抗PF4/ヘパリン複合体抗体測定の臨床的意義. 血栓止血誌 2013 ; 24 : 380-6.
 
10) 松尾武文. 透析患者のヘパリン起因性血小板減少症に対する酵素免疫測定法による抗PF4/ヘパリン複合体抗体 (HIT抗体) 測定の現況と問題点. 透析会誌 2012 ; 45 : 1117-24.
 
11) Selleng S, et al. Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost 2010 ; 8 : 30-6.
PubMed
Warkentin TE, Greinacher A : Laboratory testing for heparin-induced thrombocytopenia. In : Warkentin TE, et al., eds. Heparin-Induced Thrombocytopenia. 5th ed. New York : CRC Press ; 2012.
 

第5章 標準治療と新規薬剤

P.215 掲載の参考文献
1) Eikelboom JW, et al. Antiplatelet drugs : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 ; 141 (2 suppl) : e89S-119S.
 
2) Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994 ; 330 : 1287-94.
PubMed
3) Cattaneo M. New P2Y (12) inhibitors. Circulation 2010 ; 121 : 171-9.
PubMed
4) Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 ; 324 : 71-86.
PubMed
5) Patrono C, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005 ; 353 : 2373-83.
PubMed
6) 松下正. 処置・手術時の抗凝固薬, 抗血小板薬の扱い. Medicina 2011 ; 48 : 1798-802.
 
7) 藤本一眞ほか. 抗血栓薬服用者に対する消化器内視鏡診療ガイドライン. Gastroenterological Endoscopy 2012 ; 54 : 2073-102.
 
8) Abraham NS, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines : a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010 ; 105 : 2533-49.
PubMed
P.227 掲載の参考文献
1) Hart RG, et al. Meta-analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007 ; 146 : 857-67.
PubMed
2) 2006-2007年合同研究班報告 (班長 : 小川聡). 心房細動治療 (薬物) ガイドライン (2008年改訂版). Circ J 2008 ; 72 (Suppl. IV) : 1581-638.
 
3) Rosendaal FR, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993 ; 69 : 236-9.
PubMed
4) Connolly SJ, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008 ; 118 : 2029-37.
PubMed
5) Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 ; 361 : 1139-51.
PubMed
6) Connolly SJ, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010 ; 363 : 1875-6.
 
7) Patel MR, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011 ; 365 : 883-91.
PubMed
8) Granger CB, et al. Apixaban versus warfarin in patients with atrial fibriallation. N Engl J Med 2011 ; 365 : 981-92.
 
9) Singer DE, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009 ; 151 : 297-305.
PubMed
10) Heidbuchel H, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013 ; 15 : 625-51.
 
P.237 掲載の参考文献
1) Ito T, Maruyama I. Thrombomodulin : protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost 2011 ; 9 Suppl 1 : 168-73.
 
2) Delvaeye M, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009 ; 361 : 345-57.
PubMed
3) Ikezoe T, et al. Thrombomodulin protects endothelial cells from a calcineurin inhibitorinduced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling. Arterioscler Thromb Vasc Biol 2012 ; 32 : 2259-70.
PubMed
4) Saito H, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007 ; 5 : 31-41.
PubMed
5) Mimuro J, et al. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res 2013 ; 131 : 436-43.
PubMed
6) Ikezoe T, et al. Thrombomodulin enhances the antifibrinolytic and antileukemic effects of all-trans retinoic acid in acute promyelocytic leukemia cells. Exp Hematol 2012 ; 40 : 457-65.
PubMed
7) S hirahata A, et al. Recombinant soluble human thrombomodulin (thrombomodulin alfa) in the treatment of neonatal disseminated intravascular coagulation. Eur J Pediatr 2014 ; 173 : 303-11.
 
P.247 掲載の参考文献
1) 厚生労働省, 編. 血小板濃厚液の適正使用. 血液製剤の使用にあたって. 第4版. じほう : 東京 ; 2009.
 
2) Schiffer CA, et al. Platelet transfusion for patients with cancer : clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001 ; 19 : 1519-38.
 
3) British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003 ; 122 : 10-23.
PubMed
4) Koreth R, et al. Measurement of bleeding severity : a critical review. Transfusion 2004 ; 44 : 605-17.
PubMed
5) Estcourt LJ, et al. Platelet transfusions for patients with haematological malignancies : who needs them? Br J Haematol 2011 ; 154 : 425-40.
PubMed
6) Wandt H, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies : an open-label, multicentre, randomised study. Lancet 2012 ; 380 : 1309-16.
PubMed
7) Stanworth SJ, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 2013 ; 368 : 1771-80.
PubMed
P.256 掲載の参考文献
1) 厚生労働省. 血液製剤の使用指針. 平成21年2月20日改正.
 
2) 高見昭良. 新鮮凍結血漿. 朝倉英策, 編著. 臨床に直結する血栓止血学. 東京 : 中外医学社 ; 2013. pp.349-51.
 
3) Holcomb JB, et al. Damage control resuscitation : directly addressing the early coagulopathy of trauma. J Trauma 2007 ; 62 : 307-10.
PubMed
4) Sihler KC, Napolitano LM. Massive transfusion : new insights. Chest 2009 ; 136 : 1654-67.
PubMed
5) Duchesne JC, et al. Damage control resuscitation : the new face of damage control. J Trauma 2010 ; 69 : 976-90.
PubMed
6) 高松純樹. 大量出血時における濃縮フィブリノゲン製剤, クリオプレシピテートの有効性. 血栓止血誌 2010 ; 21 : 409-11.
 

第6章 血栓・止血の検査値をどう読むか

P.272 掲載の参考文献
1) 森下英理子. 出血性素因の検査の進め方. 朝倉英策, 編. 臨床に直結する血栓止血学. 東京 : 中外医学社 ; 2013. pp.20-5.
 
2) 天野景裕. 後天性血友病Aに関する凝血学的検査の注意点. 臨床病理 2009 ; 57 : 999-1003.
Medical*Online
3) 天野景裕. 血液凝固因子. medicina 2010 ; 47 (増刊) ; 107-9.
 
P.283 掲載の参考文献
1) Vivaldi P, et al. Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. Haematologica 1997 ; 82 : 345-7.
PubMed
2) 内藤澄悦ほか. ヘパリン治療のモニタリングにおける種々のAPTT試薬およびヘパリン投与量の相関性に関する検討. 日本検査血液学会雑誌 2012 ; 13 : 160-6.
 
3) Lui CY, et al. Defective thrombin binding by abnormal fibrin associated with recurrent thrombosis. Thromb Haemost 1979 ; 42 : 79 (Abstr).
 
4) Lijnen HR, et al. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrinenhanced plasminogen activation. Thromb Haemost 1984 ; 51 : 108-9.
PubMed
5) 新井盛大. 線溶系の分子マーカー. 日本検査血液学会, 編. スタンダード検査血液学. 第2版. 東京 : 医歯薬出版 ; 2008. pp.177-81.
 
6) Ieko M, et al. Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis. Clin Chim Acta 2007 ; 386 : 38-45.
PubMed
7) 森下英理子. アンチトロンビン, プロテインC, プロテインS. 朝倉英策, 編. 臨床に直結する血栓止血学. 東京 : 中外医学社 ; 2013. pp.51-6.
 
8) Miyata T, et al. Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. Thromb Res 2009 ; 124 : 14-8.
PubMed
9) Nakabayashi T, et al. Protein C Sapporo (protein C Glu 25 → Lys) : a heterozygous missense mutation in the Gla domain provides new insight into the interaction between protein C and endothelial protein C receptor. Thromb Haemost 2005 ; 94 : 942-50.
 
10) Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 ; 4 : 295-306.
 
P.290 掲載の参考文献
1) Kathiresan S, et al. Case records of the Massachusetts General Hospital. Case 14-2005. A 38-year-old man with fever and blurred vision. N Engl J Med 2005 ; 352 : 2003-12.
PubMed
2) 門野岳史, 大原國章. Type I クリオグロブリン血症の1例. 皮膚科の臨床 1998 ; 40 : 1639-42.
 
3) 小寺雅也, 佐藤伸一. 血栓止血異常と皮疹の種類, 鑑別. 血栓止血誌 2008 ; 19 : 339-43.
 
4) 川上民裕. 血管炎. Derma 2011 ; 176 : 1-10.
 
5) 戸田憲一. 網状皮斑 (リベド) livedo. 日皮会誌 2012 ; 122 : 2283-7.
 
6) 石黒直子. 皮膚科における血栓・塞栓症. 日皮会誌 2012 ; 122 : 2289-93.
 

書評

最近チェックした商品履歴

Loading...